Tracking Lenacapavir Rollout

To ensure that the opportunities of Lenacapavir (LEN) for PrEP, and PrEP choice generally, are finally seized and not squandered, a diverse array of stakeholders must act on the following top priorities over the next five years (2024-2028) with the product and with the programs that facilitate access.

These graphics outline the immediate next steps on the pathways to access and impact, key actors responsible for them, timelines for completion, and important progress updates. Move your cursor over the bars to see more details on the key steps and status of each activity.

Additional Resources

• Gears of Lenacapavir for PrEP Rollout — This document outlines a focused plan for LEN for PrEP rollout over the next few years, specifying priorities by stakeholder and evaluating volume and pricing strategies. The report as a whole details a coordinated response to this historic opportunity to ensure rapid implementation, equitable access, and sustainable impact.
• From Clinical Trial Efficacy to Public Health Impact: A Plan for Accelerating Access to Injectable Lenacapavir for PrEP — This plan provides a broad view of all the moving parts and identifies actions and actors responsible for ensuring time is not wasted and opportunity not squandered.
• The Lens on LEN: The Basics on Injectable Lenacapavir as PrEP — This advocates’ primer provides background on Lenacapavir for PrEP and its trials; a summary of the early findings of PURPOSE 1 & 2; key questions and next steps.